Biohacking leader Dave Asprey says the FDA has no business banning peptides
An FDA panel backed six restricted peptides for compounding. Dave Asprey told The Jason Rantz Show the agency never had authority to restrict them at all.
An FDA advisory panel recommended six of seven restricted peptides for compounding pharmacies, overruling the agency's own career scientists. (Jason Rantz)
(Jason Rantz)
An FDA advisory panel voted last month to recommend six of seven restricted peptides for compounding pharmacies, and the father of the biohacking movement Dave Asprey says the agency should never have had the authority to pull them off the market in the first place.
The Pharmacy Compounding Advisory Committee met July 23 and 24 and backed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A Bulks List, rejecting only emideltide.
Every one of those votes went against the written recommendation of FDA career scientists, who concluded that none of the seven met the agency’s evidentiary standard. The FDA is not bound by the panel and has not acted yet. Asprey sees the vote as a correction rather than a favor.
The authority question
“But the big question we should all be asking ourselves is why is the FDA doing this, and what authority do they have to do it? I don’t recall this being in the Constitution. This isn’t the government’s job,” Asprey explained on The Jason Rantz Show on Seattle Red 770 AM.
Asprey was equally unimpressed with the agency’s record.
“But look at the FDA’s track record. COVID, they kind of screwed that one up. And then you look at what they’ve done. They’ve approved drugs for Alzheimer’s that they admitted didn’t work, and they did it for PR reasons, and they’ve approved just just hundreds of drugs that either don’t work or allowed claims that don’t work. So their track record’s terrible. FDA approval just means that someone paid for it. It doesn’t mean that it works,” he said.
Asprey pointed to BPC-157, the compound Health Secretary Robert F. Kennedy Jr. has credited for his own injury recovery.
“I know hundreds of people who’ve healed injuries that wouldn’t heal with BPC 157. It’s just a peptide. These are common signaling molecules in the body, so we need to get the FDA to understand their job. This is not it,” he told listeners.
Who benefits from keeping them restricted
Asked where the pressure originates, Asprey did not put it on the bureaucrats.
“Well, the FDA, and it’s hard to blame the FDA here. It’s the big pharma companies that are manipulating certain people at the FDA that are the real problem. Almost all of the leaders of the FDA work for big pharma companies, the former leaders, and so there’s a revolving door,” he said.
That argument tracks with what Asprey told Rantz in May, when he said the Biden FDA banned cheap peptides while protecting Ozempic. The 2023 restrictions cited safety risks including cancer and liver, kidney, and heart problems.
The gray market is the actual alternative
Asprey’s practical case is that restriction does not stop peptide use, which has exploded amongst biohackers.
“We can either buy them from the same Chinese labs that made fentanyl that was imported to the U.S., or we’re going to buy them from U.S.-based compounding pharmacies that make U.S. jobs. So there’s just no economic or moral argument for blocking people’s access to things they’re going to do anyway. These are not addictive. They are not drugs. They’re natural compounds,” Asprey argued.
Critics have gone after the panel rather than the science. The FDA replaced academics and researchers with clinicians who prescribe, produce, or promote peptides, according to a MyNorthwest report on the committee’s roster. Seattle Red has previously noted that the AP’s BPC-157 coverage quoted no physicians who use the compound.
Asprey drew a line between the agency’s core job and this one. Food safety, he said, is worth doing well.
“It’s a necessary and important government function, and I’m glad they do that. But this peptide stuff, guys, get back in your lane,” Asprey said.
Listen to The Jason Rantz Show on weekday afternoons from 3 p.m. – 7 p.m. on Seattle Red on 770 AM (HD Radio 97.3 FM HD-Channel 3). Subscribe to the podcast here. Follow Jason Rantz on X, Instagram, YouTube, and Facebook.






Comments
0 Comments